Aeglea BioTherapeutics Overview
Latest ROE for Aeglea BioTherapeutics: -16.25% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-16.25%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for AGLE is -16.25%. That is below the Healthcare sector average of 21.28%. Investors often review this figure alongside Aeglea BioTherapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, AGLE currently prints -16.25% for ROE, while the sector average sits near 21.28%. That is roughly 176.4% below the sector mean. Large gaps often invite a closer look at Aeglea BioTherapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Aeglea BioTherapeutics converts resources into returns. At -16.25%, AGLE may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting AGLE's ROE (-16.25%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Aeglea BioTherapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
